Colorectal Cancer

Treating patients with unresectable colorectal liver metastases with radiofrequency ablation and chemotherapy resulted in improved long-term overall survival.

Neoadjuvant mFOLFOX6 plus radiation improved pathologic complete response in advanced rectal cancer patients compared with 5-FU/radiation or mFOLFOX6 alone.

Increased levels of vitamin D were associated with improved overall survival rates in metastatic colorectal cancer patients treated as part of CALGB/SWOG 80405.

Colorectal tumors that lacked the ability to repair DNA were found to be highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

The CONCUR trial found that regorafenib improved overall survival in a large group of Asian patients with treatment-refractory metastatic colorectal cancer.

TAS-102, an oral combination of trifluridine and tipiracil hydrochloride, improved median overall survival in patients with refractory colorectal cancer.

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Metastatic colorectal cancer patients had about a 1.5-month increase in overall survival when treated with second-line ramucirumab plus FOLFIRI vs FOLFIRI alone.

Patients who had either laparoscopic surgery or open surgery for localized rectal cancer had similar overall survival and disease-free survival rates.

Men with high midlife cardiorespiratory fitness have a lower incidence of lung and colorectal cancer; however, this association was not seen for prostate cancer.

If US colorectal cancer screening is increased to 80% by 2018, a new study predicts a decrease in both cancer incidence and mortality within 20 years.

Although genomic testing can improve the cost-effectiveness of a treatment, assessing the cost-effectiveness of genomic testing outside the context of its impact on treatment is not practical.

The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.

Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.

Looking at a large group of early-onset colorectal cancer patients, only 1.3% had TP53 mutations, none of whom met criteria for Li-Fraumeni syndrome.

In a large study, it was found that those who ate a vegetarian diet had a lower risk of colorectal cancer compared with their non-vegetarian counterparts.

Bevacizumab as first-line therapy for metastatic CRC equated to an incremental cost-effectiveness ratio of more than half a million dollars per QALY.

Patients with lung and colorectal cancer who understood that chemotherapy would not cure them were no less likely to receive chemotherapy at the end of life.

Adding cetuximab to FOLFIRI resulted in improvements in survival and objective response in patients with KRAS codon exon 2 wild-type metastatic colorectal cancer.

The TKI famitinib was associated with a significant PFS improvement in metastatic colorectal cancer patients, according to the results of a phase II study.

The addition of ramucirumab to second-line FOLFIRI resulted in a delay in disease progression and improved survival in metastatic colorectal cancer patients.

Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with chemotherapy and a targeted agent.

Rectal cancer patients who completed neoadjuvant therapy with a clinical complete response had similar 4-year survival rates as patients who opted for surgery.

Initial treatment with FOLFOXIRI plus bevacizumab in metastatic colorectal cancer patients improved survival over FOLFIRI and bevacizumab by more than 4 months.